EssexBio

Essex-Bio Group

简繁 EN

ANNOUNCEMENTS

Normative Disclosure, Honest Communication

Select category

ANNOUNCEMENTS SHAREHOLDER INFORMATION

Select time

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Date

Title

File

Times

2021-08-30

SUPPLEMENTAL ANNOUNCEMENT RELATING TO DISCLOSEABLE TRANSACTION PRODUCT INTERESTS TRANSFER AGREEMENT RELATING TO IODIZED LECITHIN CAPSULES

2445

2021-08-12

INTERIM DIVIDEND FOR THE SIX MONTHS ENDED 30 JUNE 2021

2430

2021-08-12

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021

2598

2021-07-29

NOTICE OF BOARD MEETING

2567

2021-07-20

POSITIVE PROFIT ALERT

2461

2021-07-19

VOLUNTARY ANNOUNCEMENT FIRST PATIENT FIRST VISIT COMPLETED IN THE PRC IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS RELATING TO THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION

2583

2021-06-09

DISCLOSEABLE TRANSACTION PRODUCT INTERESTS TRANSFER AGREEMENT RELATING TO IODIZED LECITHIN CAPSULES

2842

2021-05-17

VOLUNTARY ANNOUNCEMENT UNAUDITED OPERATING STATISTICS FOR THE FOUR MONTHS ENDED 30 APRIL 2021

2572

2021-05-12

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 12 MAY 2021

2363

2021-04-20

VOLUNTARY ANNOUNCEMENT FURTHER UPDATE IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS RELATING TO THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION

2817

2021-04-07

INSIDE INFORMATION APPROVAL TO COMMERCIALISE PRESERVATIVE-FREE UNIT-DOSE MOXIFLOXACIN HYDROCHLORIDE EYE DROPS IN THE PRC

2640

2021-03-25

NOTICE OF ANNUAL GENERAL MEETING

2738

2021-03-25

FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, 12 MAY 2021 (or any adjournment thereof)

2566

2021-03-25

PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING

2805

2021-03-19

VOLUNTARY ANNOUNCEMENT FURTHER UPDATE IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS RELATING TO THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION

2510

2021-03-12

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2020

2729

2021-03-02

NOTICE OF BOARD MEETING

2545

2021-03-01

CHANGE OF ADDRESS OF PRINCIPAL SHARE REGISTRAR AND TRANSFER AGENT IN THE CAYMAN ISLANDS

2381

2021-02-24

INSIDE INFORMATION FURTHER UPDATES IN RELATION TO CO-DEVELOPMENT AGREEMENT - POSITIVE OUTCOME OF U.S. FDA SECOND PHASE 3 CLINICAL TRIAL IN DRY EYE DISEASE

2444

2021-02-22

NSIDE INFORMATION FURTHER UPDATES IN RELATION TO CO-DEVELOPMENT AGREEMENT - U.S. FDA SECOND PHASE 3 CLINICAL TRIAL ("VISTA-2") IN DRY EYE DISEASE

2517

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT